Diagnostics firm finalizes Matritech acquisition

Article

Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test.

Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test.

The BladderChek is a point-of-care test cleared by the FDA for both the diagnosis and monitoring of bladder cancer. Inverness is an international developer of point-of-care diagnostics related to infectious disease, cardiology, oncology, drugs of abuse, and women’s health.

“Matritech’s expertise in the development of protein-based diagnostic products for the early detection of cancer is a terrific addition to the Inverness portfolio of products and capabilities, said Ron Zwanziger, CEO of Inverness.

Related Videos
Dr. Christopher Wallis in an interview with Urology Times
Randall A. Lee, MD, answers a question during a Zoom video interview
Edward M. Schaeffer, MD, PhD, answers a Zoom video interview question
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
James Ferguson III, MD, PhD, answers a question during a Zoom video interview
Nicholas L. Kavoussi, MD, answers a question during a Zoom video interview
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
© 2023 MJH Life Sciences

All rights reserved.